SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Courtesy of Michael Vi/Getty Images
Drug Development
Boehringer Bags First FDA Approval for Rare Skin Disease
Boehringer announced that the FDA approved Spevigo for generalized pustular psoriasis flares in adults, the first drug approved for this indication.
September 2, 2022
 · 
2 min read
 · 
Tristan Manalac
Businessperson Walking Out With Exit Sign On Wall
Drug Development
Following Takeda’s Exit, Finch Slashes Headcount, Pauses Trial
Finch announced that it is slashing its headcount by around 37% and suspending its planned Phase I study in autism a week after Takeda withdrew from its multi-year collaboration.
September 2, 2022
 · 
2 min read
 · 
Tristan Manalac
Policy
AstraZeneca Wins Injunction, Blocking Former Exec from Joining GSK
A High Court judge in London granted AstraZeneca an injunction, temporarily blocking a former executive from joining rival pharma GSK.
September 1, 2022
 · 
2 min read
 · 
Tristan Manalac
Chesnot/Getty Images
Drug Development
Sanofi Wins FDA Approval for First ASMD Drug
Sanofi announced FDA approval of Xenpozyme for adult and pediatric patients with the rare genetic disease acid sphingomyelinase deficiency, often referred to as Niemann-Pick disease.
September 1, 2022
 · 
3 min read
 · 
Tristan Manalac
Business
Money on the Move: Mesoblast, Iantrek, Jenavalve and More
Mesoblast fell short of analyst forecasts this week, and money is pouring into glaucoma, medical devices for heart disease and chronic endocrine conditions.
August 31, 2022
 · 
4 min read
 · 
Tristan Manalac
Al Seib / Los Angeles Times via Getty
Drug Development
Amgen Puts Pressure on Mirati with Phase III Lung Cancer Win
Amgen announced Tuesday that initial Phase III data of Lumakras in KRAS G12C-mutated NSCLC met the primary endpoint of progression-free survival.
August 31, 2022
 · 
3 min read
 · 
Tristan Manalac
Business
With $50M, Vilya’s Peptides Aim to Transcend Cells’ Lipid Membrane
Vilya will use its funds for cutting-edge computational techniques to develop innovative drugs for difficult-to-treat diseases.
August 30, 2022
 · 
2 min read
 · 
Tristan Manalac
Kena Betancur/VIEWpress/Corbis via Getty
Drug Development
Bayer’s Kerendia Shows Competitive Profile in Type 2 Diabetes-Related CKD
Phase III data shows the potential of Bayer’s Kerendia to reduce the risk of all-cause and cardiovascular mortality in type 2 diabetes patients with chronic kidney disease.
August 29, 2022
 · 
2 min read
 · 
Tristan Manalac
VCG via Getty Images
Drug Development
Despite Stumbles, Bayer, BMS & Janssen Moving Forward with XIa Inhibitors
Factor XIa inhibitors developed by Bayer and the duo of BMS and Janssen Pharmaceuticals missed Phase II endpoints in data presented at ESC.
August 29, 2022
 · 
3 min read
 · 
Tristan Manalac
Courtesy of Sundry Photography/Getty Images, Tom B
Deals
Pricing Debate Stalls Merck-Seagen Acquisition Deal
Merck’s bid to buy the cancer-focused Seagen has hit a roadblock after the two companies failed to agree on a price, according to a Bloomberg report.
August 26, 2022
 · 
2 min read
 · 
Tristan Manalac
Photo shows professional holding box of work-relat
Business
Zymergen Cuts 80 More Jobs, Parts Ways with Co-Founder
In an SEC filing, Zymergen revealed it was cutting 80 more jobs and parting with Zach Serber, its co-founder and chief scientific officer.
August 26, 2022
 · 
2 min read
 · 
Tristan Manalac
David L. Ryan/The Boston Globe via Getty Images
Pharm Country
NEJM Study: Omicron Blunts Pfizer’s Paxlovid in Younger Adults
According to a recent study, Pfizer’s Paxlovid appeared to be far more effective at reducing deaths and hospitalizations in older adults than younger patients suffering from the Omicron variant of COVID-19.
August 25, 2022
 · 
3 min read
 · 
Tristan Manalac
Harold Cunningham/Getty Images
Genetown
Novartis Spins Off Sandoz to Maximize Growth of Pharmaceuticals, Biosimilars
Novartis unveiled plans to separate its generics and biosimilars arm, Sandoz, into a standalone entity, allowing both to pursue independent and more business-appropriate growth strategies.
August 25, 2022
 · 
3 min read
 · 
Tristan Manalac
Job Trends
Sonoma, Thermo Fisher Bring Jobs to Seattle, WA & Plainville, MA - Updated
Sonoma Bio announced its plans to erect an 83,000-square-foot operations facility in Seattle, while Thermo Fisher opened a new viral vector manufacturing plant in Massachusetts.
August 24, 2022
 · 
3 min read
 · 
Tristan Manalac
male hands with wrist watch is considered American dollars. Hands holding dollar cash. 1000 dollars in 100 bills in a man's hand close-up on a dark background. hundred
Business
Money on the Move: AdvanCell, eTheRNA, Bluejay and More
Money is now flowing into promising platforms for prostate cancer from AdvanCell, mRNA therapeutics from eTheRNA, hepatitis from Bluejay and more.
August 24, 2022
 · 
5 min read
 · 
Tristan Manalac
Load More